Clinical characterisation of exacerbations of severe eosinophilic asthma occurring on mepolizumab and placebo
Bibliographic record
Abstract
Mepolizumab, a monoclonal antibody targeting IL-5, depletes circulating eosinophils and reduces exacerbations of severe eosinophilic asthma [1]. However, some people continue to exacerbate potentially due to different, less corticosteroid responsive mechanisms [2]. To characterise the changes in symptom and lung function seen in on-biologic exacerbations, we conducted a post-hoc comparison of diary card data from prednisolone-treated exacerbations occurring during treatment with mepolizumab or placebo in three placebo-controlled trials [1, 3, 4]. Footnotes This manuscript has recently been accepted for publication in the ERJ Open Research . It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJOR online. Please open or download the PDF to view this article. Conflict of interest: DJB and SWY are employees of GSK and hold stock/stock options in GSK. SWY has since retired. GH and RS have no relevant competing interests to disclose. Conflict of interest: IP reports personal fees from AstraZeneca, GSK, Boehringer Ingelheim, Sanofi/Regeneron, Circassia, Merck, Novartis, Mundipharma, Teva, Knopp. Grants and personal fees from Chiesi, Afferent. LH reports personal fees or sponsorship from AstraZeneca, Boehringer Ingelheim, GSK, Novartis, Roche/Genentech, Sanofi, Amgen, Aerocrine, Napp. Grants from AstraZeneca, Boehringer Ingelheim, GSK and Napp.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.003 | 0.005 |
| Meta-epidemiology (narrow) | 0.000 | 0.000 |
| Meta-epidemiology (broad) | 0.002 | 0.001 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.000 | 0.000 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.002 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".